## Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

#### ACHILLION PHARMACEUTICALS INC

Form 4

November 02, 2006

FORM 4		OMB
1 OI tivi 7	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549	OMB
	Washington, D.C. 20549	Number:
Check this box	S ,	Expires:

**OMB APPROVAL OMB** 

3235-0287 Number: January 31,

2005 Estimated average 0.5

> X\_\_ 10% Owner Other (specify

burden hours per response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading SCHRODER VENTURE Issuer Symbol MANAGERS LTD **ACHILLION** PHARMACEUTICALS INC

[ACHN]

(Last) (First) (Middle) 3. Date of Earliest Transaction

(Month/Day/Year) 10/31/2006

(Check all applicable)

SCHRODER ADMINISTRATIVE SERVICES, 22 CHURCH STREET

> (Street) 4. If Amendment, Date Original

> > Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Director

below)

Officer (give title

Form filed by One Reporting Person \_X\_ Form filed by More than One Reporting Person

HAMILTON, D0 HM 11

(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired (A) 5. Amount of 7. Nature of

Security (Month/Day/Year) Execution Date, if (Instr. 3) (Month/Day/Year)

Transactionr Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)

Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect

(Instr. 4)

Indirect Beneficial Ownership (Instr. 4)

or (Instr. 3 and 4) Amount Price (D)

(A)

Code V

Common 1,710,231 10/31/2006 C Α (1) Stock

\$0  $1,710,231 \frac{(1)}{}$  I

See Footnote (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of tiorDerivative Securities ) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Series B Convertible Preferred Stock	(2)	10/31/2006		С		6,071,204 (3) (5)	<u>(2)</u>	<u>(4)</u>	Common Stock	758,89 (3) (5)
Series C Convertible Preferred Stock	(2)	10/31/2006		С		3,306,866 (5) (6)	(2)	<u>(4)</u>	Common Stock	494,28 (5) (6)
Series C-2 Convertible Preferred Stock	(2)	10/31/2006		С		3,656,461 (5) (7)	(2)	<u>(4)</u>	Common Stock	457,05 (5) (7)

# **Reporting Owners**

Reporting Owner Name / Address	Director	Relations 10% Owner	ships Officer	Other
SCHRODER VENTURE MANAGERS LTD SCHRODER ADMINISTRATIVE SERVICES 22 CHURCH STREET HAMILTON, D0 HM 11		X		
SCHRODER VENTURES INTERNATIONAL LIFE SCIENCES FUND II LP1 SCHRODER ADMINISTRATIVE SERVICES 22 CHURCH STREET HAMILTON, D0 HM 11		X		
Schroder Ventures International Life Sciences Fund II L.P.2 SCHRODER ADMINISTRATIVE SERVICES 22 CHURCH STREET HAMILTON, D0 HM-11		X		
Schroder Ventures International Life Sciences Fund II Strategic Partners L.P. SCHRODER ADMINISTRATIVE SERVICES 22 CHURCH STREET HAMILTON, D0 HM 11		X		
		X		

Reporting Owners 2

## Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

Schroder Ventures International Life Sciences Fund II L.P.3

SCHRODER ADMINSITRATIVE SERVICES

22 CHURCH STREET

HAMILTON, D0 HM-11

SV (Nominees) LTD as Nominee of Schroder Ventures Investments LTD

SCHRODER ADMINISTRATIVE SERVICES

22 CHURCH STREET

HAMILTON, D0 HM 11

SCHRODER VENTURES MANAGERS INC

SCHRODER ADMINSITRATIVE SERVICES

22 CHURCH STREET

HAMILTON, D0 HM11

SITCO Nominees Ltd. VC 01903 as Nominee of Schroder Ventures International

Life Sciences Fund II Group Co-Investment Scheme

SCHRODER ADMINISTRATIVE SERVICES LIMITED

22 CHURCH STREET

HAMILTON, D0 HM-11

# **Signatures**

/s/ Schroder Venture Managers Ltd. by Deborah Speight, Director and Scott Burns, Authorized Signatory

11/02/2006

X

X

X

\*\*Signature of Reporting Person

Date

(see signatures on Exhibit 99.2)

11/02/2006

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) See "Notes to Footnote 1" on Exhibit 99.1
- Upon the closing of the issuer's initial public offering, each share of Series B and Series C-2 Convertible Preferred Stock automatically converted into approximately 0.125 shares of common stock and each share of Series C Convertible Preferred Stock automatically converted into approximately 0.149 shares of common stock. The Series B, Series C and Series C-2 Convertible Preferred Stock conversion rates reflect the 1-for-8 reverse stock split, which became effective on October 24, 2006.
- (3) See "Notes to Footnote 3" on Exhibit 99.1
- (4) Not applicable
- (5) Includes shares of preferred stock issued as a dividend which was paid upon the conversion of the preferred stock.
- (6) See "Notes to Footnote 6" on Exhibit 99.1
- (7) See "Notes to Footnote 7" on Exhibit 99.1

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3